← Leaderboards
Susanna S Park
University Of California At Davis
$2,617,130
Attributed
$2,617,130
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $611.2K · FY2018–22$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,617,130 · 1
By mechanism
UG1$2,617,130 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California At Davis
Same institution · by research overlap
- Sara Michelle Thomasy$8,532,621
- Richard M. Levenson$15,762,754
- Clare E Yellowley-Genetos$3,162,129
- Dake Hao$600,475
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAffectAge-YearsAspirate SubstanceAutologousBlindnessBlood CirculationBlood VesselsBoneBone CellBone MarrowBone Marrow AspirationBone Marrow CellsBone Marrow InvolvementBone Marrow TransplantationCaliforniaCardiomyopathiesCd34 GeneCellsCell TherapyChronicClinical TrialsCross-Over StudiesAcute
Grant awards (5)
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$535,631
UG1 · FY2022 · EY · contact PI
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$611,158
UG1 · FY2021 · EY · contact PI
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$472,056
UG1 · FY2020 · EY · contact PI
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$533,301
UG1 · FY2019 · EY · contact PI
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$464,984
UG1 · FY2018 · EY · contact PI